Sorry, you need to enable JavaScript to visit this website.

GEODON® (ziprasidone HCl) Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use GEODON safely and effectively. See full prescribing information for GEODON.

GEODON® (ziprasidone HCl) capsules
GEODON® (ziprasidone mesylate) injection for intramuscular use Initial U.S. Approval: 2001

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

See full prescribing information for complete boxed warning.

  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death (5.1)
  • GEODON is not approved for elderly patients with dementia-related psychosis (5.1)

RECENT MAJOR CHANGES

Boxed Warning 11/2018
Dosage and Administration (2.4) Removed 11/2018
Warnings and Precautions (5.1, 5.2) 11/2018

INDICATIONS AND USAGE

GEODON is an atypical antipsychotic. In choosing among treatments, prescribers should be aware of the capacity of GEODON to prolong the QT interval and may consider the use of other drugs first (5.3)

GEODON is indicated as an oral formulation for the:

  • Treatment of schizophrenia. (1)
  • Acute treatment as monotherapy of manic or mixed episodes associated with bipolar I disorder. (1)
  • Maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate. (1)

GEODON as an intramuscular injection is indicated for the:

  • Acute treatment of agitation in schizophrenic patients. (1)

DOSAGE AND ADMINISTRATION

Give oral doses with food.

  • Schizophrenia: Initiate at 20 mg twice daily. Daily dosage may be adjusted up to 80 mg twice daily. Dose adjustments should occur at intervals of not less than 2 days. Safety and efficacy has been demonstrated in doses up to 100 mg twice daily. The lowest effective dose should be used. (2.1)
  • Acute treatment of manic/mixed episodes of bipolar I disorder: Initiate at 40 mg twice daily. Increase to 60 mg or 80 mg twice daily on day 2 of treatment. Subsequent dose adjustments should be based on tolerability and efficacy within the range of 40–80 mg twice daily. (2.2)
  • Maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate: Continue treatment at the same dose on which the patient was initially stabilized, within the range of 40–80 mg twice daily. (2.2)
  • Acute treatment of agitation associated with schizophrenia (intramuscular administration): 10 mg–20 mg up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every 2 hours. Doses of 20 mg may be administered every 4 hours. (2.3)

DOSAGE FORMS AND STRENGTHS

  • Capsules: 20 mg, 40 mg, 60 mg, and 80 mg (3)
  • Intramuscular injection: 20 mg/mL single-use vials (3)

CONTRAINDICATIONS

  • Do not use in patients with a known history of QT prolongation (4.1)
  • Do not use in patients with recent acute myocardial infarction (4.1)
  • Do not use in patients with uncompensated heart failure (4.1)
  • Do not use in combination with other drugs that have demonstrated QT prolongation (4.1)
  • Do not use in patients with known hypersensitivity to ziprasidone (4.2)

WARNINGS AND PRECAUTIONS

  • Cerebrovascular Adverse Reactions in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e.g., stroke, transient ischemic attack). (5.2)
  • QT Interval Prolongation: GEODON use should be avoided in patients with bradycardia, hypokalemia or hypomagnesemia, congenital prolongation of the QT interval, or in combination with other drugs that have demonstrated QT prolongation. (5.3)
  • Neuroleptic Malignant Syndrome (NMS): Potentially fatal symptom complex has been reported with antipsychotic drugs. Manage with immediate discontinuation of drug and close monitoring. (5.4)
  • Severe Cutaneous Adverse Reactions, such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and Stevens-Johnson syndrome has been reported with ziprasidone exposure. DRESS and other Severe Cutaneous Adverse Reactions (SCAR) are sometimes fatal. Discontinue GEODON if DRESS or SCAR are suspected.(5.5)
  • Tardive Dyskinesia: May develop acutely or chronically. (5.6)
  • Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/ cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia, and weight gain. (5.7)
  • Hyperglycemia and Diabetes Mellitus (DM): Monitor all patients for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Patients with DM risk factors should undergo blood glucose testing before and during treatment. (5.7)
  • Dyslipidemia: Undesirable alterations have been observed in patients treated with atypical antipsychotics. (5.7)
  • Weight Gain: Weight gain has been reported. Monitor weight gain. (5.7)
  • Rash: Discontinue in patients who develop a rash without an identified cause. (5.8)
  • Orthostatic Hypotension: Use with caution in patients with known cardiovascular or cerebrovascular disease. (5.9)
  • Leukopenia, Neutropenia, and Agranulocytosis has been reported with antipsychotics. Patients with a pre-existing low white blood cell count (WBC) or a history of leukopenia/neutropenia should have their complete blood count (CBC) monitored frequently during the first few months of therapy and should discontinue GEODON at the first sign of a decline in WBC in the absence of other causative factors. (5.11)
  • Seizures: Use cautiously in patients with a history of seizures or with conditions that lower seizure threshold. (5.12)
  • Potential for Cognitive and Motor impairment: Patients should use caution when operating machinery. (5.13)
  • Suicide: Closely supervise high-risk patients. (5.18)

ADVERSE REACTIONS

Commonly observed adverse reactions (incidence ≥5% and at least twice the incidence for placebo) were:

  • Schizophrenia: Somnolence, respiratory tract infection. (6.1)
  • Manic and Mixed Episodes Associated with Bipolar Disorder: Somnolence, extrapyramidal symptoms, dizziness, akathisia, abnormal vision, asthenia, vomiting. (6.1)
  • Intramuscular administration (≥5% and at least twice the lowest intramuscular ziprasidone group): Headache, nausea, somnolence. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

  • Ziprasidone should not be used in combination with other drugs that have demonstrated QT prolongation. (4.1, 7.3)
  • The absorption of ziprasidone is increased up to two-fold in the presence of food. (7.10)
  • The full prescribing information contains additional drug interactions. (7).

USE IN SPECIFIC POPULATIONS

  • Pregnancy: Ziprasidone should be used during pregnancy only if the potential benefit justifies the potential risk. (8.1)
  • Nursing Mothers: Breast feeding is not recommended. (8.3)
  • Pediatric Use: Safety and effectiveness for pediatric patients has not been established. (8.4)
  • Renal Impairment: Intramuscular ziprasidone should be administered with caution to patients with impaired renal function as the cyclodextrin excipient is cleared by renal filtration. (8.6)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 11/2018

What's New

No Current Announcements.

Therapeutic Area

Contact Pfizer Medical

Search

Please enter your search term(s) for GEODON®

Contact Pfizer

Need to report an Adverse Event, Side Effect or Product Quality Concern?

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: (800) 438-1985

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns at 1-800-FDA-1088 or www.fda.gov/MedWatch

Have a Medical Question on a Pfizer Prescription Medicine?
Contact Pfizer Medical Information to speak with a professional regarding your medical question on a Pfizer prescription product: (800) 438-1985
Have a Question on a Pfizer Over-the-Counter Product?
For Pfizer Consumer Healthcare non-prescription or over-the-counter products such as Advil, Centrum, Nexium or Thermacare, call (800) 322-3129
Have a Question about Pfizer Clinical Trials?
If you are looking for information about Pfizer studies currently recruiting new patients in your area, you can begin your search on our website. For questions about a Pfizer Clinical Trial, call (800) 718-1021 or email [email protected]
Need Information on Pfizer’s Patient Assistance Programs?

Pfizer RxPathways® connects eligible patients, regardless of their insurance status, to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. For more information, please call (844) 989-7284 or visit www.PfizerRxPathways.com.

Eligible patients can register for valuable savings offers for nearly 40 brand name medications. Visit www.MyPfizerBrands.com for more information.